In NSCLC, the high expression of N-cadherin is not only related to tumor stage, differentiation degree and clinical prognosis, but is also closely related to gefitinib resistance and lung cancer brain metastasis [13,14,15]. Here, CDH2 is linked to non-small cell lung carcinoma.